Standard
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis : a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR). / Dreyer, L; Magyari, M; Laursen, B; Cordtz, R; Sellebjerg, F; Locht, H.
I:
Scandinavian Journal of Rheumatology, Bind 45, Nr. sup128, PP31, 2016.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Dreyer, L, Magyari, M, Laursen, B, Cordtz, R
, Sellebjerg, F & Locht, H 2016, '
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR)',
Scandinavian Journal of Rheumatology, bind 45, nr. sup128, PP31.
https://doi.org/10.1080/03009742.2016.1207299APA
Dreyer, L., Magyari, M., Laursen, B., Cordtz, R.
, Sellebjerg, F., & Locht, H. (2016).
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR).
Scandinavian Journal of Rheumatology,
45(sup128), [PP31].
https://doi.org/10.1080/03009742.2016.1207299Vancouver
Dreyer L, Magyari M, Laursen B, Cordtz R
, Sellebjerg F, Locht H.
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR).
Scandinavian Journal of Rheumatology. 2016;45(sup128). PP31.
https://doi.org/10.1080/03009742.2016.1207299Author
Dreyer, L ; Magyari, M ; Laursen, B ; Cordtz, R ; Sellebjerg, F ; Locht, H. / Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis : a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR). I: Scandinavian Journal of Rheumatology. 2016 ; Bind 45, Nr. sup128.
Bibtex
@article{802dd9f71c96434bb8f99ad7d4dedf6a,
title = "Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR)",
author = "L Dreyer and M Magyari and B Laursen and R Cordtz and F Sellebjerg and H Locht",
year = "2016",
doi = "10.1080/03009742.2016.1207299",
language = "English",
volume = "45",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Taylor & Francis",
number = "sup128",
}
RIS
TY - ABST
T1 - Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis
T2 - a population-based study from DANBIO and the Danish Multiple Sclerosis Registry (DMSR)
AU - Dreyer, L
AU - Magyari, M
AU - Laursen, B
AU - Cordtz, R
AU - Sellebjerg, F
AU - Locht, H
PY - 2016
Y1 - 2016
U2 - 10.1080/03009742.2016.1207299
DO - 10.1080/03009742.2016.1207299
M3 - Conference abstract in journal
VL - 45
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
SN - 0300-9742
IS - sup128
M1 - PP31
ER -
